From: Tubal ligation, hysterectomy and ovarian cancer: A meta-analysis
Number of contributing studies | Random-effects RR (95%CI) | |
---|---|---|
Study design | 30 studies | |
Cohort study | 0.67 (0.50, 0.90) | |
Case-control study | 0.70 (0.63, 0.75) | |
Other study design | 0.95 (0.63, 1.43) | |
BRCA status | 30 studies | |
BRCA positive | 0.64 (0.43, 0.96) | |
General population | 0.70 (0.64, 0.76) | |
Geographic location | 30 studies | |
US | 0.68 (0.63, 0.73) | |
Non-US | 0.71 (0.61, 0.82) | |
Histologic subtype | 11 studies | |
Serous | 0.75 (0.65,0.88) | |
Endometrioid | 0.45 (0.33,0.61) | |
Mucinous | 0.88 (0.70,1.09) | |
Clear cell | 0.72 (0.55,0.94) | |
Other | 0.80 (0.63,1.01) | |
Age at tubal ligation | 7 studies | |
<35 years of age | 0.69 (0.59,0.81) | |
35+ years of age | 0.79 (0.68,0.92) | |
Years since tubal ligation | 6 studies | |
<10 years | 0.69 (0.59,0.79) | |
10+ years | 0.68 (0.54,0.87) |